Prophylactic effects of chitin microparticles on highly pathogenic H5N1 influenza virus
Identifieur interne : 001B24 ( PascalFrancis/Corpus ); précédent : 001B23; suivant : 001B25Prophylactic effects of chitin microparticles on highly pathogenic H5N1 influenza virus
Auteurs : Takeshi Ichinohe ; Noriyo Nagata ; Peter Strong ; Shin-Ichi Tamura ; Hidehiro Takahashi ; Ai Ninomiya ; Masaki Imai ; Takato Odagiri ; Masato Tashiro ; Hirofumi Sawa ; Joe Chiba ; Takeshi Kurata ; Tetsutaro Sata ; Hideki HasegawaSource :
- Journal of medical virology [ 0146-6615 ] ; 2007.
Descripteurs français
- Pascal (Inist)
English descriptors
Abstract
Highly pathogenic avian influenza virus (H5N1) is an emerging pathogen with the potential to cause great harm to humans, and there is concern about the potential for a new influenza pandemic. This virus is resistant to the antiviral effects of interferons and tumor necrosis factor-α. However, the mechanism of interferon-independent protective innate immunity is not well understood. The prophylactic effects of chitin microparticles as a stimulator of innate mucosal immunity against a recently obtained strain of H5N1 influenza virus infection were examined in mice. Clinical parameters and the survival rate of mice treated by intranasal application of chitin microparticles were significantly improved compared to non-treated mice after a lethal influenza virus challenge. Flow cytometric analysis revealed that the number of natural killer cells that expressed tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and that had migrated into the cervical lymph node was markedly increased (26-fold) after intranasal treatment with chitin microparticles. In addition, the level of IL-6 and interferon-gamma-inducible protein-10 (IP-10) in the nasal mucosa after H5N1 influenza virus challenge was decreased by prophylactictreatmentwith chitin microparticles. These results suggest that prophylactic intranasal administration of chitin microparticles enhanced the local accumulation of natural killer cells and suppressed hyper-induction of cytokines, resulting in an innate immune response to prevent pathogenesis of H5N1 influenza virus.
Notice en format standard (ISO 2709)
Pour connaître la documentation sur le format Inist Standard.
pA |
|
---|
Format Inist (serveur)
NO : | PASCAL 07-0263587 INIST |
---|---|
ET : | Prophylactic effects of chitin microparticles on highly pathogenic H5N1 influenza virus |
AU : | ICHINOHE (Takeshi); NAGATA (Noriyo); STRONG (Peter); TAMURA (Shin-Ichi); TAKAHASHI (Hidehiro); NINOMIYA (Ai); IMAI (Masaki); ODAGIRI (Takato); TASHIRO (Masato); SAWA (Hirofumi); CHIBA (Joe); KURATA (Takeshi); SATA (Tetsutaro); HASEGAWA (Hideki) |
AF : | Department of Pathology, National Institute of Infectious Diseases, Gakuen/Musashimurayama-shi, Tokyo/Japon (1 aut., 2 aut., 4 aut., 5 aut., 12 aut., 13 aut., 14 aut.); Department of Biological Science and Technology, Tokyo University of Science, Yamazaki/Noda, Chiba/Japon (1 aut., 11 aut.); CMP Therapeutics Ltd/Oxford/Royaume-Uni (3 aut.); Department of Virology III, National Institute of Infectious Diseases, Gakuen/Musashimurayama-shi, Tokyo/Japon (6 aut., 7 aut., 8 aut., 9 aut.); Department of Molecular Pathobiology, 21st Century COE Program for Zoonosis Control, Hokkaido University Research Center for Zoonosis Control/Kita-ku, Sapporo/Japon (10 aut.) |
DT : | Publication en série; Niveau analytique |
SO : | Journal of medical virology; ISSN 0146-6615; Coden JMVIDB; Etats-Unis; Da. 2007; Vol. 79; No. 6; Pp. 811-819; Bibl. 3/4 p. |
LA : | Anglais |
EA : | Highly pathogenic avian influenza virus (H5N1) is an emerging pathogen with the potential to cause great harm to humans, and there is concern about the potential for a new influenza pandemic. This virus is resistant to the antiviral effects of interferons and tumor necrosis factor-α. However, the mechanism of interferon-independent protective innate immunity is not well understood. The prophylactic effects of chitin microparticles as a stimulator of innate mucosal immunity against a recently obtained strain of H5N1 influenza virus infection were examined in mice. Clinical parameters and the survival rate of mice treated by intranasal application of chitin microparticles were significantly improved compared to non-treated mice after a lethal influenza virus challenge. Flow cytometric analysis revealed that the number of natural killer cells that expressed tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and that had migrated into the cervical lymph node was markedly increased (26-fold) after intranasal treatment with chitin microparticles. In addition, the level of IL-6 and interferon-gamma-inducible protein-10 (IP-10) in the nasal mucosa after H5N1 influenza virus challenge was decreased by prophylactictreatmentwith chitin microparticles. These results suggest that prophylactic intranasal administration of chitin microparticles enhanced the local accumulation of natural killer cells and suppressed hyper-induction of cytokines, resulting in an innate immune response to prevent pathogenesis of H5N1 influenza virus. |
CC : | 002A05C10; 002B05C02J; 002A05C04 |
FD : | Influenzavirus; Prévention; Pouvoir pathogène; Immunité naturelle; Grippe aviaire |
FG : | Orthomyxoviridae; Virus; Infection; Virose |
ED : | Influenzavirus; Prevention; Pathogenicity; Natural immunity; Avian influenza |
EG : | Orthomyxoviridae; Virus; Infection; Viral disease |
SD : | Influenzavirus; Prevención; Poder patógeno; Inmunidad natural; Gripe aviar |
LO : | INIST-17422.354000149577660210 |
ID : | 07-0263587 |
Links to Exploration step
Pascal:07-0263587Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Prophylactic effects of chitin microparticles on highly pathogenic H5N1 influenza virus</title>
<author><name sortKey="Ichinohe, Takeshi" sort="Ichinohe, Takeshi" uniqKey="Ichinohe T" first="Takeshi" last="Ichinohe">Takeshi Ichinohe</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Pathology, National Institute of Infectious Diseases, Gakuen</s1>
<s2>Musashimurayama-shi, Tokyo</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Department of Biological Science and Technology, Tokyo University of Science, Yamazaki</s1>
<s2>Noda, Chiba</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Nagata, Noriyo" sort="Nagata, Noriyo" uniqKey="Nagata N" first="Noriyo" last="Nagata">Noriyo Nagata</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Pathology, National Institute of Infectious Diseases, Gakuen</s1>
<s2>Musashimurayama-shi, Tokyo</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Strong, Peter" sort="Strong, Peter" uniqKey="Strong P" first="Peter" last="Strong">Peter Strong</name>
<affiliation><inist:fA14 i1="03"><s1>CMP Therapeutics Ltd</s1>
<s2>Oxford</s2>
<s3>GBR</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tamura, Shin Ichi" sort="Tamura, Shin Ichi" uniqKey="Tamura S" first="Shin-Ichi" last="Tamura">Shin-Ichi Tamura</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Pathology, National Institute of Infectious Diseases, Gakuen</s1>
<s2>Musashimurayama-shi, Tokyo</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Takahashi, Hidehiro" sort="Takahashi, Hidehiro" uniqKey="Takahashi H" first="Hidehiro" last="Takahashi">Hidehiro Takahashi</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Pathology, National Institute of Infectious Diseases, Gakuen</s1>
<s2>Musashimurayama-shi, Tokyo</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ninomiya, Ai" sort="Ninomiya, Ai" uniqKey="Ninomiya A" first="Ai" last="Ninomiya">Ai Ninomiya</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Virology III, National Institute of Infectious Diseases, Gakuen</s1>
<s2>Musashimurayama-shi, Tokyo</s2>
<s3>JPN</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Imai, Masaki" sort="Imai, Masaki" uniqKey="Imai M" first="Masaki" last="Imai">Masaki Imai</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Virology III, National Institute of Infectious Diseases, Gakuen</s1>
<s2>Musashimurayama-shi, Tokyo</s2>
<s3>JPN</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Odagiri, Takato" sort="Odagiri, Takato" uniqKey="Odagiri T" first="Takato" last="Odagiri">Takato Odagiri</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Virology III, National Institute of Infectious Diseases, Gakuen</s1>
<s2>Musashimurayama-shi, Tokyo</s2>
<s3>JPN</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tashiro, Masato" sort="Tashiro, Masato" uniqKey="Tashiro M" first="Masato" last="Tashiro">Masato Tashiro</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Virology III, National Institute of Infectious Diseases, Gakuen</s1>
<s2>Musashimurayama-shi, Tokyo</s2>
<s3>JPN</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Sawa, Hirofumi" sort="Sawa, Hirofumi" uniqKey="Sawa H" first="Hirofumi" last="Sawa">Hirofumi Sawa</name>
<affiliation><inist:fA14 i1="05"><s1>Department of Molecular Pathobiology, 21st Century COE Program for Zoonosis Control, Hokkaido University Research Center for Zoonosis Control</s1>
<s2>Kita-ku, Sapporo</s2>
<s3>JPN</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Chiba, Joe" sort="Chiba, Joe" uniqKey="Chiba J" first="Joe" last="Chiba">Joe Chiba</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Biological Science and Technology, Tokyo University of Science, Yamazaki</s1>
<s2>Noda, Chiba</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kurata, Takeshi" sort="Kurata, Takeshi" uniqKey="Kurata T" first="Takeshi" last="Kurata">Takeshi Kurata</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Pathology, National Institute of Infectious Diseases, Gakuen</s1>
<s2>Musashimurayama-shi, Tokyo</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Sata, Tetsutaro" sort="Sata, Tetsutaro" uniqKey="Sata T" first="Tetsutaro" last="Sata">Tetsutaro Sata</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Pathology, National Institute of Infectious Diseases, Gakuen</s1>
<s2>Musashimurayama-shi, Tokyo</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hasegawa, Hideki" sort="Hasegawa, Hideki" uniqKey="Hasegawa H" first="Hideki" last="Hasegawa">Hideki Hasegawa</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Pathology, National Institute of Infectious Diseases, Gakuen</s1>
<s2>Musashimurayama-shi, Tokyo</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">07-0263587</idno>
<date when="2007">2007</date>
<idno type="stanalyst">PASCAL 07-0263587 INIST</idno>
<idno type="RBID">Pascal:07-0263587</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001B24</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Prophylactic effects of chitin microparticles on highly pathogenic H5N1 influenza virus</title>
<author><name sortKey="Ichinohe, Takeshi" sort="Ichinohe, Takeshi" uniqKey="Ichinohe T" first="Takeshi" last="Ichinohe">Takeshi Ichinohe</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Pathology, National Institute of Infectious Diseases, Gakuen</s1>
<s2>Musashimurayama-shi, Tokyo</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Department of Biological Science and Technology, Tokyo University of Science, Yamazaki</s1>
<s2>Noda, Chiba</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Nagata, Noriyo" sort="Nagata, Noriyo" uniqKey="Nagata N" first="Noriyo" last="Nagata">Noriyo Nagata</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Pathology, National Institute of Infectious Diseases, Gakuen</s1>
<s2>Musashimurayama-shi, Tokyo</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Strong, Peter" sort="Strong, Peter" uniqKey="Strong P" first="Peter" last="Strong">Peter Strong</name>
<affiliation><inist:fA14 i1="03"><s1>CMP Therapeutics Ltd</s1>
<s2>Oxford</s2>
<s3>GBR</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tamura, Shin Ichi" sort="Tamura, Shin Ichi" uniqKey="Tamura S" first="Shin-Ichi" last="Tamura">Shin-Ichi Tamura</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Pathology, National Institute of Infectious Diseases, Gakuen</s1>
<s2>Musashimurayama-shi, Tokyo</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Takahashi, Hidehiro" sort="Takahashi, Hidehiro" uniqKey="Takahashi H" first="Hidehiro" last="Takahashi">Hidehiro Takahashi</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Pathology, National Institute of Infectious Diseases, Gakuen</s1>
<s2>Musashimurayama-shi, Tokyo</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ninomiya, Ai" sort="Ninomiya, Ai" uniqKey="Ninomiya A" first="Ai" last="Ninomiya">Ai Ninomiya</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Virology III, National Institute of Infectious Diseases, Gakuen</s1>
<s2>Musashimurayama-shi, Tokyo</s2>
<s3>JPN</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Imai, Masaki" sort="Imai, Masaki" uniqKey="Imai M" first="Masaki" last="Imai">Masaki Imai</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Virology III, National Institute of Infectious Diseases, Gakuen</s1>
<s2>Musashimurayama-shi, Tokyo</s2>
<s3>JPN</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Odagiri, Takato" sort="Odagiri, Takato" uniqKey="Odagiri T" first="Takato" last="Odagiri">Takato Odagiri</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Virology III, National Institute of Infectious Diseases, Gakuen</s1>
<s2>Musashimurayama-shi, Tokyo</s2>
<s3>JPN</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tashiro, Masato" sort="Tashiro, Masato" uniqKey="Tashiro M" first="Masato" last="Tashiro">Masato Tashiro</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Virology III, National Institute of Infectious Diseases, Gakuen</s1>
<s2>Musashimurayama-shi, Tokyo</s2>
<s3>JPN</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Sawa, Hirofumi" sort="Sawa, Hirofumi" uniqKey="Sawa H" first="Hirofumi" last="Sawa">Hirofumi Sawa</name>
<affiliation><inist:fA14 i1="05"><s1>Department of Molecular Pathobiology, 21st Century COE Program for Zoonosis Control, Hokkaido University Research Center for Zoonosis Control</s1>
<s2>Kita-ku, Sapporo</s2>
<s3>JPN</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Chiba, Joe" sort="Chiba, Joe" uniqKey="Chiba J" first="Joe" last="Chiba">Joe Chiba</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Biological Science and Technology, Tokyo University of Science, Yamazaki</s1>
<s2>Noda, Chiba</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kurata, Takeshi" sort="Kurata, Takeshi" uniqKey="Kurata T" first="Takeshi" last="Kurata">Takeshi Kurata</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Pathology, National Institute of Infectious Diseases, Gakuen</s1>
<s2>Musashimurayama-shi, Tokyo</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Sata, Tetsutaro" sort="Sata, Tetsutaro" uniqKey="Sata T" first="Tetsutaro" last="Sata">Tetsutaro Sata</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Pathology, National Institute of Infectious Diseases, Gakuen</s1>
<s2>Musashimurayama-shi, Tokyo</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hasegawa, Hideki" sort="Hasegawa, Hideki" uniqKey="Hasegawa H" first="Hideki" last="Hasegawa">Hideki Hasegawa</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Pathology, National Institute of Infectious Diseases, Gakuen</s1>
<s2>Musashimurayama-shi, Tokyo</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Journal of medical virology</title>
<title level="j" type="abbreviated">J. med. virol.</title>
<idno type="ISSN">0146-6615</idno>
<imprint><date when="2007">2007</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Journal of medical virology</title>
<title level="j" type="abbreviated">J. med. virol.</title>
<idno type="ISSN">0146-6615</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Avian influenza</term>
<term>Influenzavirus</term>
<term>Natural immunity</term>
<term>Pathogenicity</term>
<term>Prevention</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Influenzavirus</term>
<term>Prévention</term>
<term>Pouvoir pathogène</term>
<term>Immunité naturelle</term>
<term>Grippe aviaire</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Highly pathogenic avian influenza virus (H5N1) is an emerging pathogen with the potential to cause great harm to humans, and there is concern about the potential for a new influenza pandemic. This virus is resistant to the antiviral effects of interferons and tumor necrosis factor-α. However, the mechanism of interferon-independent protective innate immunity is not well understood. The prophylactic effects of chitin microparticles as a stimulator of innate mucosal immunity against a recently obtained strain of H5N1 influenza virus infection were examined in mice. Clinical parameters and the survival rate of mice treated by intranasal application of chitin microparticles were significantly improved compared to non-treated mice after a lethal influenza virus challenge. Flow cytometric analysis revealed that the number of natural killer cells that expressed tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and that had migrated into the cervical lymph node was markedly increased (26-fold) after intranasal treatment with chitin microparticles. In addition, the level of IL-6 and interferon-gamma-inducible protein-10 (IP-10) in the nasal mucosa after H5N1 influenza virus challenge was decreased by prophylactictreatmentwith chitin microparticles. These results suggest that prophylactic intranasal administration of chitin microparticles enhanced the local accumulation of natural killer cells and suppressed hyper-induction of cytokines, resulting in an innate immune response to prevent pathogenesis of H5N1 influenza virus.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0146-6615</s0>
</fA01>
<fA02 i1="01"><s0>JMVIDB</s0>
</fA02>
<fA03 i2="1"><s0>J. med. virol.</s0>
</fA03>
<fA05><s2>79</s2>
</fA05>
<fA06><s2>6</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Prophylactic effects of chitin microparticles on highly pathogenic H5N1 influenza virus</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>ICHINOHE (Takeshi)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>NAGATA (Noriyo)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>STRONG (Peter)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>TAMURA (Shin-Ichi)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>TAKAHASHI (Hidehiro)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>NINOMIYA (Ai)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>IMAI (Masaki)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>ODAGIRI (Takato)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>TASHIRO (Masato)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>SAWA (Hirofumi)</s1>
</fA11>
<fA11 i1="11" i2="1"><s1>CHIBA (Joe)</s1>
</fA11>
<fA11 i1="12" i2="1"><s1>KURATA (Takeshi)</s1>
</fA11>
<fA11 i1="13" i2="1"><s1>SATA (Tetsutaro)</s1>
</fA11>
<fA11 i1="14" i2="1"><s1>HASEGAWA (Hideki)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Pathology, National Institute of Infectious Diseases, Gakuen</s1>
<s2>Musashimurayama-shi, Tokyo</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Biological Science and Technology, Tokyo University of Science, Yamazaki</s1>
<s2>Noda, Chiba</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>11 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>CMP Therapeutics Ltd</s1>
<s2>Oxford</s2>
<s3>GBR</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Department of Virology III, National Institute of Infectious Diseases, Gakuen</s1>
<s2>Musashimurayama-shi, Tokyo</s2>
<s3>JPN</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Department of Molecular Pathobiology, 21st Century COE Program for Zoonosis Control, Hokkaido University Research Center for Zoonosis Control</s1>
<s2>Kita-ku, Sapporo</s2>
<s3>JPN</s3>
<sZ>10 aut.</sZ>
</fA14>
<fA20><s1>811-819</s1>
</fA20>
<fA21><s1>2007</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>17422</s2>
<s5>354000149577660210</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2007 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>3/4 p.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>07-0263587</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Journal of medical virology</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Highly pathogenic avian influenza virus (H5N1) is an emerging pathogen with the potential to cause great harm to humans, and there is concern about the potential for a new influenza pandemic. This virus is resistant to the antiviral effects of interferons and tumor necrosis factor-α. However, the mechanism of interferon-independent protective innate immunity is not well understood. The prophylactic effects of chitin microparticles as a stimulator of innate mucosal immunity against a recently obtained strain of H5N1 influenza virus infection were examined in mice. Clinical parameters and the survival rate of mice treated by intranasal application of chitin microparticles were significantly improved compared to non-treated mice after a lethal influenza virus challenge. Flow cytometric analysis revealed that the number of natural killer cells that expressed tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and that had migrated into the cervical lymph node was markedly increased (26-fold) after intranasal treatment with chitin microparticles. In addition, the level of IL-6 and interferon-gamma-inducible protein-10 (IP-10) in the nasal mucosa after H5N1 influenza virus challenge was decreased by prophylactictreatmentwith chitin microparticles. These results suggest that prophylactic intranasal administration of chitin microparticles enhanced the local accumulation of natural killer cells and suppressed hyper-induction of cytokines, resulting in an innate immune response to prevent pathogenesis of H5N1 influenza virus.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002A05C10</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B05C02J</s0>
</fC02>
<fC02 i1="03" i2="X"><s0>002A05C04</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Influenzavirus</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Influenzavirus</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Influenzavirus</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Prévention</s0>
<s5>05</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Prevention</s0>
<s5>05</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Prevención</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Pouvoir pathogène</s0>
<s5>06</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Pathogenicity</s0>
<s5>06</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Poder patógeno</s0>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Immunité naturelle</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Natural immunity</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Inmunidad natural</s0>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Grippe aviaire</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Avian influenza</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Gripe aviar</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Orthomyxoviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Orthomyxoviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Orthomyxoviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Infection</s0>
<s5>13</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Infection</s0>
<s5>13</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Infección</s0>
<s5>13</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Virose</s0>
<s5>16</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Viral disease</s0>
<s5>16</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Virosis</s0>
<s5>16</s5>
</fC07>
<fN21><s1>176</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 07-0263587 INIST</NO>
<ET>Prophylactic effects of chitin microparticles on highly pathogenic H5N1 influenza virus</ET>
<AU>ICHINOHE (Takeshi); NAGATA (Noriyo); STRONG (Peter); TAMURA (Shin-Ichi); TAKAHASHI (Hidehiro); NINOMIYA (Ai); IMAI (Masaki); ODAGIRI (Takato); TASHIRO (Masato); SAWA (Hirofumi); CHIBA (Joe); KURATA (Takeshi); SATA (Tetsutaro); HASEGAWA (Hideki)</AU>
<AF>Department of Pathology, National Institute of Infectious Diseases, Gakuen/Musashimurayama-shi, Tokyo/Japon (1 aut., 2 aut., 4 aut., 5 aut., 12 aut., 13 aut., 14 aut.); Department of Biological Science and Technology, Tokyo University of Science, Yamazaki/Noda, Chiba/Japon (1 aut., 11 aut.); CMP Therapeutics Ltd/Oxford/Royaume-Uni (3 aut.); Department of Virology III, National Institute of Infectious Diseases, Gakuen/Musashimurayama-shi, Tokyo/Japon (6 aut., 7 aut., 8 aut., 9 aut.); Department of Molecular Pathobiology, 21st Century COE Program for Zoonosis Control, Hokkaido University Research Center for Zoonosis Control/Kita-ku, Sapporo/Japon (10 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Journal of medical virology; ISSN 0146-6615; Coden JMVIDB; Etats-Unis; Da. 2007; Vol. 79; No. 6; Pp. 811-819; Bibl. 3/4 p.</SO>
<LA>Anglais</LA>
<EA>Highly pathogenic avian influenza virus (H5N1) is an emerging pathogen with the potential to cause great harm to humans, and there is concern about the potential for a new influenza pandemic. This virus is resistant to the antiviral effects of interferons and tumor necrosis factor-α. However, the mechanism of interferon-independent protective innate immunity is not well understood. The prophylactic effects of chitin microparticles as a stimulator of innate mucosal immunity against a recently obtained strain of H5N1 influenza virus infection were examined in mice. Clinical parameters and the survival rate of mice treated by intranasal application of chitin microparticles were significantly improved compared to non-treated mice after a lethal influenza virus challenge. Flow cytometric analysis revealed that the number of natural killer cells that expressed tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and that had migrated into the cervical lymph node was markedly increased (26-fold) after intranasal treatment with chitin microparticles. In addition, the level of IL-6 and interferon-gamma-inducible protein-10 (IP-10) in the nasal mucosa after H5N1 influenza virus challenge was decreased by prophylactictreatmentwith chitin microparticles. These results suggest that prophylactic intranasal administration of chitin microparticles enhanced the local accumulation of natural killer cells and suppressed hyper-induction of cytokines, resulting in an innate immune response to prevent pathogenesis of H5N1 influenza virus.</EA>
<CC>002A05C10; 002B05C02J; 002A05C04</CC>
<FD>Influenzavirus; Prévention; Pouvoir pathogène; Immunité naturelle; Grippe aviaire</FD>
<FG>Orthomyxoviridae; Virus; Infection; Virose</FG>
<ED>Influenzavirus; Prevention; Pathogenicity; Natural immunity; Avian influenza</ED>
<EG>Orthomyxoviridae; Virus; Infection; Viral disease</EG>
<SD>Influenzavirus; Prevención; Poder patógeno; Inmunidad natural; Gripe aviar</SD>
<LO>INIST-17422.354000149577660210</LO>
<ID>07-0263587</ID>
</server>
</inist>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/PascalFrancis/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001B24 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 001B24 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= PandemieGrippaleV1 |flux= PascalFrancis |étape= Corpus |type= RBID |clé= Pascal:07-0263587 |texte= Prophylactic effects of chitin microparticles on highly pathogenic H5N1 influenza virus }}
![]() | This area was generated with Dilib version V0.6.34. | ![]() |